Search Results for "establish"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for establish. Results 621 to 630 of 656 total matches.
Lixisenatide for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017 (Issue 1513)
relationship has not
been established.1
The most common adverse effect of the insulin
glargine/lixisenatide ...
The FDA has approved lixisenatide (Sanofi), a short-acting
injectable GLP-1 (glucagon-like peptide-1)
receptor agonist, for once-daily treatment of adults
with type 2 diabetes, both alone (Adlyxin) and in a
fixed-ratio combination with insulin glargine (Soliqua
100/33). Lixisenatide has been available since 2013 in
many other countries as Lyxumia. It is the fifth GLP-1
receptor agonist to be approved in the US.
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018 (Issue 1559)
products, but whether they affect the drugs'
efficacy or safety remains to be established.
Suppression ...
The FDA has approved two subcutaneously
injected calcitonin gene-related peptide (CGRP)
antagonists, fremanezumab-vfrm (Ajovy – Teva) and
galcanezumab-gnlm (Emgality – Lilly), for migraine
prevention in adults. Fremanezumab and galcanezumab
are the second and third subcutaneously
injected monoclonal antibodies that target the CGRP
pathway to be approved by the FDA for this indication;
erenumab-aooe (Aimovig), which targets the CGRP
receptor, was the first.
Istradefylline (Nourianz) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
in efficacy and tolerability to other adjunctive
drugs for PD is not established, but it appeared to be
less ...
The FDA has approved istradefylline (Nourianz —
Kyowa Kirin), an oral adenosine A2A receptor antagonist,
for use as an adjunct to carbidopa/levodopa in adults
with Parkinson's disease (PD) who experience "off"
episodes. Istradefylline is the first adenosine A2A
receptor antagonist to be approved in the US; it has
been available in Japan since 2013.
Expanded Table: Some Vaccines for Adults (online only)
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
or immunosuppression
Pregnancy: safety and efficacy are not
established
Special Populations: recommended
$171.60 ...
Drugs for Depression
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023 (Issue 1691)
other antidepressants for this use has not been established.4 Vortioxetine’s adverse effect profile is similar ...
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR, and
others), and mirtazapine (Remeron, and others) are
reasonable alternatives. Improvement in symptoms
can occur within the first two weeks of treatment
with these drugs, but a substantial benefit may not be
achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200 doi:10.58347/tml.2023.1691a | Show Introduction Hide Introduction
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
remain to be
established.
Fecal microbiota transplant (FMT) has been investigated for
treatment of IBS ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D), mixed type
(IBS-M), or unclassified (IBS-U). Since the exact cause
of IBS is unknown, the goal of treatment is symptom
control. Some over-the-counter (OTC) products and
prescription drugs for IBS are listed in Tables 1-4. The
safety of these drugs during pregnancy and lactation
is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24 doi:10.58347/tml.2025.1721a | Show Introduction Hide Introduction
Varenicline (Chantix) for Tobacco Dependence
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006 (Issue 1241)
remains to be
established. Nausea is a frequent adverse effect. The
long-term safety of varenicline ...
Varenicline tartrate (Chantix - Pfizer) is now available for oral treatment of tobacco dependence. Some other drugs for this indication are listed in this article.
Drugs That May Cause Psychiatric Symptoms
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008 (Issue 1301)
to establish.
Psychiatric symptoms that emerge during drug treatDrugs That May Cause Psychiatric
Symptoms ...
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Click here to view the free full article.
Click here to view the free full article.
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017 (Issue 1531)
%)
was not sufficient to establish noninferiority with 12
weeks of Epclusa (98%). In POLARIS-3, the SVR12
rate was 96 ...
The FDA has approved Mavyret (Abbvie) and Vosevi
(Gilead), two new fixed-dose combinations of direct-acting
antiviral (DAA) drugs, for treatment of chronic
hepatitis C virus (HCV) infection caused by any of the
six major HCV genotypes in patients without cirrhosis
or with compensated cirrhosis. Both are approved for
use in treatment-experienced patients. Mavyret is also
approved for treatment-naive patients.
Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
-policy.
5. For moderate or severe primary infection. Clinical trial data establishing the efficacy ...
The recommendations for treatment of varicella-zoster
virus (VZV) and herpes simplex virus (HSV)
infections are listed in tables 1 and 2. Vaccination
against VZV was reviewed in a previous issue.